---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000037"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:51:26.659319+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Presents Preclinical Data on KB801 Gene Therapy for Neurotrophic Keratitis at ARVO 2025

## Summary
- KB801 is a topical HSV-1-based vector encoding human NGF for neurotrophic keratitis, disclosed in an 8-K filed May 5, 2025.
- In vitro, KB801 transduction of primary human corneal epithelial cells resulted in dose-dependent secretion of mature, functional NGF protein.
- In a murine corneal wound model, a single topical KB801 dose produced higher peak NGF (491 pg/eye) and prolonged exposure (t1/2 55.5 hrs) vs. rhNGF (t1/2 83 min).
- After eight weekly topical KB801 doses, eyes showed only mild inflammatory infiltrate with no necrosis; all resolved by 27 days post-treatment.
- Poster presented at ARVO 2025 Annual Meeting in Salt Lake City, Utah on May 5, 2025.

## SEC filing metadata
- accession: 0001711279-25-000037
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000037/0001711279-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000037/krys-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000037
- JSON: https://secwatch.observer/filing/0001711279-25-000037.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.